Modeling effects of XXXX on disease progression of bone mineral density in collagen-induced arthritic @entity35 .

@entity5272 @entity9248 @entity9170 @entity9249 @entity568 @entity604 @entity619 @entity3426 @entity35
A mechanism-based model was developed to characterize the crosstalk between proinflammatory cytokines, bone remodeling biomarkers, and bone mineral density (BMD) in collagen-induced arthritic (CIA) @entity35 . Male Lewis @entity35 were divided into five groups: healthy control, CIA control, CIA receiving single 0.225  mg  kg(-1) subcutaneous (SC) @entity619 ( @entity9170 ), CIA receiving single 2.25  mg  kg(-1) SC @entity9170 , and CIA receiving chronic 0.225  mg  kg(-1) SC @entity9170 . The CIA @entity35 underwent collagen induction at day 0 and @entity9170 was injected at day 21 post-induction. Disease activity was monitored throughout the study and @entity35 were sacrificed at different time points for blood and paw collection. Protein concentrations of @entity3426 , @entity568 ligand ( @entity9248 ), @entity9249 ( @entity9249 ), and @entity5272 -resistant acid phosphatase 5b (TRACP-5b) in paws were measured by enzyme-linked immunosorbent assays (ELISA). Disease progression and @entity9170 pharmacodynamic profiles of @entity3426 , @entity568 , @entity9248 , and @entity9249 were fitted simultaneously and parameters were sequentially applied to fit the TRACP-5b and BMD data. The model was built according to the mechanisms reported in the literature and modeling was performed using ADAPT 5 software with na  ve pooling. Time profiles of @entity3426 and @entity568 protein concentrations correlated with their mRNAs. The @entity9248 and @entity9249 profiles matched previous findings in CIA @entity35 . @entity9170 inhibited the expressions of @entity3426 , @entity568 , and @entity9248 , but did not alter @entity9249 . TRACP-5b was also inhibited by @entity9170 . Model predictions suggested that anti- @entity3426 therapy and anti- @entity9248 therapy would result in similar efficacy for prevention of @entity604 among the cytokine antagonists.
